-
公开(公告)号：US08030456B2
公开(公告)日：2011-10-04
申请号：US12335328
申请日：2008-12-15
申请人： Daniel H. S. Lee , R. Blake Pepinsky , Weiwei Li , Jane K. Relton , Dane S. Worley , Stephen M. Strittmatter , Dinah W. Y. Sah , Sylvia A. Rabacchi
发明人： Daniel H. S. Lee , R. Blake Pepinsky , Weiwei Li , Jane K. Relton , Dane S. Worley , Stephen M. Strittmatter , Dinah W. Y. Sah , Sylvia A. Rabacchi
CPC分类号： C07K14/705 , A61K2039/505 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2319/00 , C07K2319/30 , Y10S530/809
摘要： Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
摘要翻译： 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白以及编码其的核酸的制备和使用方法。
-
公开(公告)号：US20090099078A1
公开(公告)日：2009-04-16
申请号：US12162256
申请日：2007-01-26
申请人： Daniel H.S. Lee , Dingyi Wen , R. Blake Pepinsky , Jane K. Relton , Xinzhong Wang , Alexey Lugovskoy , Werner Meier , Ellen A. Garber , Laura Silvian , Paul H. Weinreb
发明人： Daniel H.S. Lee , Dingyi Wen , R. Blake Pepinsky , Jane K. Relton , Xinzhong Wang , Alexey Lugovskoy , Werner Meier , Ellen A. Garber , Laura Silvian , Paul H. Weinreb
CPC分类号： C07K14/705 , A01K67/027 , A01K67/0275 , A01K2217/058 , A01K2227/105 , A01K2267/0356 , A61K38/179 , A61K39/3955 , A61K48/00 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C07K2319/33 , C07K2319/74 , C12N15/1136 , C12N15/1138 , C12N15/8509 , C12N2310/111 , C12N2310/14 , C12N2310/53
摘要： Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
摘要翻译： 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码相同的核苷酸和拮抗剂多核苷酸的制备和使用方法。
-
公开(公告)号：US07442370B2
公开(公告)日：2008-10-28
申请号：US10356264
申请日：2003-01-31
申请人： Dinah Wen-Yee Sah , R. Blake Pepinsky , Paula Ann Boriack-Sjodin , Stephan S. Miller , Anthony Rossomando , Laura Silvian
发明人： Dinah Wen-Yee Sah , R. Blake Pepinsky , Paula Ann Boriack-Sjodin , Stephan S. Miller , Anthony Rossomando , Laura Silvian
IPC分类号： A61K38/18 , A61K31/74 , C07K14/475 , C08G63/48 , C08G63/91
CPC分类号： C07K14/475 , A61K38/00 , A61K39/00 , A61K47/60 , C07K14/4756 , C07K2319/00
摘要： A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
摘要翻译： 公开了包含与聚合物偶联的突变的新伯斯加蛋白多肽的二聚体。 这种二聚体表现出延长的生物利用度，并且在优选的实施方案中，相对于野生型形式的新霉素具有延长的生物活性。
-
公开(公告)号：US5670617A
公开(公告)日：1997-09-23
申请号：US450246
申请日：1995-05-25
IPC分类号： A61K38/00 , A61K39/00 , A61K47/48 , A61K49/00 , C07K14/025 , C07K14/16 , C07K14/21 , C07K14/47 , C12N9/08 , C12N9/22 , C12N15/62 , C12N15/87 , C07H21/00 , C07K7/00 , C07K14/00 , C07K14/155
CPC分类号： C12Y111/01007 , A61K47/48238 , A61K49/00 , C07K14/005 , C07K14/21 , C07K14/47 , C12N15/62 , C12N15/87 , C12N9/0065 , C12N9/22 , A61K2123/00 , A61K38/00 , A61K39/00 , C07K2319/00 , C07K2319/10 , C07K2319/55 , C07K2319/71 , C07K2319/80 , C12N2710/20022 , C12N2740/16322
摘要： This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation. The reduced size of the preferred transport polypeptides of this invention also minimizes interference with the biological activity of the cargo molecule.
摘要翻译： 本发明涉及生物活性物质分子如多肽和核酸在体外和体内递送到细胞的细胞质和细胞核中。 根据本发明的货物分子的细胞内递送通过使用包含HIV tat蛋白或其一个或多个部分并且共价连接到货物分子的新型转运多肽来实现。 本发明优选实施方案中的转运多肽的特征在于存在tat碱性区（氨基酸49-57），不存在富含半胱氨酸的区域（氨基酸22-36）和不存在tat外显子 2编码的天然存在的tat蛋白的羧基末端结构域（氨基酸73-86）。 由于缺乏富含半胱氨酸的区域，本发明优选的转运多肽解决了假反式激活和二硫键聚集的潜在问题。 本发明优选的转运多肽的减小的尺寸还使对货物分子的生物活性的干扰最小化。
-
45.发明授权Nucleic acids encoding and methods of making tat-derived transport polypeptides 失效核酸编码和制备tat衍生的转运多肽的方法
公开(公告)号：US5652122A
公开(公告)日：1997-07-29
申请号：US450257
申请日：1995-05-25
IPC分类号： A61K38/00 , A61K39/00 , A61K47/48 , A61K49/00 , C07K14/025 , C07K14/16 , C07K14/21 , C07K14/47 , C12N9/08 , C12N9/22 , C12N15/62 , C12N15/87 , C12P21/02 , C07H21/04 , C12N1/19 , C12N1/21
CPC分类号： C12Y111/01007 , A61K47/48238 , A61K49/00 , C07K14/005 , C07K14/21 , C07K14/47 , C12N15/62 , C12N15/87 , C12N9/0065 , C12N9/22 , A61K2123/00 , A61K38/00 , A61K39/00 , C07K2319/00 , C07K2319/10 , C07K2319/55 , C07K2319/71 , C07K2319/80 , C12N2710/20022 , C12N2740/16322
摘要： This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation. The reduced size of the preferred transport polypeptides of this invention also minimizes interference with the biological activity of the cargo molecule.
摘要翻译： 本发明涉及生物活性物质分子如多肽和核酸在体外和体内递送到细胞的细胞质和细胞核中。 根据本发明的货物分子的细胞内递送通过使用包含HIV tat蛋白或其一个或多个部分并且共价连接到货物分子的新型转运多肽来实现。 本发明优选实施方案中的转运多肽的特征在于存在tat碱性区（氨基酸49-57），不存在富含半胱氨酸的区域（氨基酸22-36）和不存在tat外显子 2编码的天然存在的tat蛋白的羧基末端结构域（氨基酸73-86）。 由于缺乏富含半胱氨酸的区域，本发明优选的转运多肽解决了假反式激活和二硫键聚集的潜在问题。 本发明优选的转运多肽的减小的尺寸还使对货物分子的生物活性的干扰最小化。
-
公开(公告)号：US5545723A
公开(公告)日：1996-08-13
申请号：US213448
申请日：1994-03-15
IPC分类号： C12N15/09 , A61K38/00 , A61K38/21 , A61K48/00 , A61P31/12 , A61P35/00 , A61P37/00 , A61P43/00 , C07H21/04 , C07K14/565 , C12N1/21 , C12N15/24 , C12P21/02 , C12R1/19 , C12N15/22
CPC分类号： C07K14/565 , A01K2217/05 , A61K38/00
摘要： A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods of using those compositions to treat viral infections, cancer or tumors or for immunomodulation.
摘要翻译： 其中phe（F），tyr（Y），trp（W）或他（H））在101位代替val（V）的IFN-β突变蛋白，当根据野生型IFN-β编号时，DNA序列 编码这些IFN-β突变蛋白的重组DNA分子，含有可操作地连接到表达控制序列并能够诱导IFN-β突变蛋白表达的重组DNA分子，用这些重组DNA分子转化的宿主，含IFN-β突变蛋白的药物组合物和 使用这些组合物来治疗病毒感染，癌症或肿瘤或用于免疫调节。
-
47.发明授权DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI 失效DNA序列，重组DNA分子和生产脂蛋白III，IV，V和VI的方法
公开(公告)号：US5484711A
公开(公告)日：1996-01-16
申请号：US162641
申请日：1993-12-03
IPC分类号： C12N1/21 , A61K38/00 , A61P17/00 , A61P27/02 , A61P27/14 , A61P29/00 , A61P37/08 , C07H21/04 , C07K14/00 , C07K14/47 , C12N15/12 , C12P21/02 , C12R1/19 , C12N15/15 , C12N15/63 , C12N15/70 , C12N15/81
CPC分类号： C07K14/4721 , A61K38/00
摘要： Human lipocortins III, IV, V and VI, DNA sequences and recombinant DNA molecules that are characterized in that they code for these human lipocortins. Hosts transformed with these sequences may be employed in the processes of this invention to produce the human lipocortin molecules of this invention. These polypeptides possess anti-inflammatory activity and are useful in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases.
摘要翻译： 人类脂蛋白III，IV，V和VI，DNA序列和重组DNA分子，其特征在于它们编码这些人类脂蛋白。 用这些序列转化的宿主可用于本发明的方法以产生本发明的人类脂质皮质分子。 这些多肽具有抗炎活性，可用于治疗关节炎，过敏，皮肤病，眼科和胶原疾病。
-
48.发明授权DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides 失效DNA序列，重组DNA分子和用于产生人磷脂酶抑制剂多肽的方法
公开(公告)号：US4879224A
公开(公告)日：1989-11-07
申请号：US690146
申请日：1985-01-10
CPC分类号： C07K14/4721 , C12N15/72 , C12N15/81 , C12N15/85 , A61K38/00
摘要： DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor polypeptide. In appropiate hosts these DNA sequences permit the production of human phospholipase inhibitor polypeptides.
摘要翻译： DNA序列，重组DNA分子和用它们转化的宿主产生人磷脂酶抑制剂多肽的方法和制备和使用这些产物的方法。 DNA序列和重组DNA分子的特征在于它们编码人磷脂酶抑制剂多肽的表达。 在适当的宿主中，这些DNA序列允许产生人磷脂酶抑制剂多肽。
-
公开(公告)号：US08119114B2
公开(公告)日：2012-02-21
申请号：US12163425
申请日：2008-06-27
申请人： Dinah Wen-Yee Sah , R. Blake Pepinsky , Paula Ann Boriack-Sjodin , Stephan S. Miller , Anthony Rossomando , Laura Silvian
发明人： Dinah Wen-Yee Sah , R. Blake Pepinsky , Paula Ann Boriack-Sjodin , Stephan S. Miller , Anthony Rossomando , Laura Silvian
CPC分类号： C07K14/475 , A61K38/00 , A61K39/00 , A61K47/60 , C07K14/4756 , C07K2319/00
摘要： A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
摘要翻译： 公开了包含与聚合物偶联的突变的新伯斯加蛋白多肽的二聚体。 这种二聚体表现出延长的生物利用度，并且在优选的实施方案中，相对于野生型形式的新霉素具有延长的生物活性。
-
公开(公告)号：US08017733B2
公开(公告)日：2011-09-13
申请号：US10892830
申请日：2004-07-16
申请人： KoChung Lin , R. Blake Pepinsky , Ling Ling Chen , Donna M. Hess , Edward Y. Lin , Russell C. Petter , Darren P. Baker
发明人： KoChung Lin , R. Blake Pepinsky , Ling Ling Chen , Donna M. Hess , Edward Y. Lin , Russell C. Petter , Darren P. Baker
CPC分类号： C08G65/329 , A61K47/60 , C08L2203/02
摘要： The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.
摘要翻译： 本发明涉及新型聚亚烷基二醇化合物及其使用方法。 特别地，包含新型聚乙二醇缀合物的化合物单独使用或与抗病毒剂组合用于治疗病毒感染，例如慢性丙型肝炎。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.048 秒)
